Medical Pharmacology Question Bank

Chapter 1: General Pharmacology — Module 5: Drug Development and Regulation
Tier: Core Concepts (CC)

BEFORE YOU BEGIN

These Core Concepts questions cover pharmacogenomics — the study of how genetic variation determines individual differences in drug response. You will work through questions on CYP2D6 metabolizer phenotypes and their clinical consequences for codeine, antidepressants, and beta-blockers; CYP2C19 variation and its impact on clopidogrel activation; CYP2C9 and VKORC1 variation in warfarin dosing; HLA-associated hypersensitivity reactions for abacavir and allopurinol; thiopurine methyltransferase testing before azathioprine; and the distinction between pharmacokinetic and pharmacodynamic genetic variation. This module explains why the same drug at the same dose produces therapeutic benefit in one patient, toxicity in another, and no effect in a third. Work through each question before reading the rationale.

1. Two patients are prescribed the same dose of a drug metabolized by a liver enzyme. Patient A has two fully functional gene copies encoding that enzyme. Patient B has two non-functional copies — a genetic variant means her enzyme does not work at all. Which of the following best predicts what will happen in each patient?

A) Patient B will have a better therapeutic response than Patient A because accumulating more drug means a stronger pharmacological effect with no associated risk of toxicity
B) Both patients will have identical responses because the liver compensates for enzyme deficiency by using alternative metabolic pathways that produce the same metabolites at the same rate
C) Patient A will metabolize the drug at a normal rate and achieve intended therapeutic concentrations; Patient B will be unable to metabolize the drug normally — it will accumulate to higher concentrations than intended, potentially causing toxicity at doses that are safe in Patient A; Patient B is classified as a poor metabolizer for this enzyme
D) The difference in enzyme activity will affect pharmacodynamics but not pharmacokinetics — both patients will have the same plasma concentration but different receptor sensitivity to the drug
E) Genetic variants in metabolizing enzymes only affect drugs given intravenously — oral drug absorption bypasses the relevant metabolic enzymes entirely

ANSWER: C

Rationale:

This question establishes the fundamental concept of pharmacogenomics: genetic variation in drug-metabolizing enzymes creates predictable differences in drug plasma concentrations between individuals. A poor metabolizer accumulates the drug to higher concentrations than a normal metabolizer — for most drugs this means greater pharmacological effect and greater risk of dose-dependent toxicity at a dose perfectly safe in a normal metabolizer. This is pharmacokinetic variation driven by genetics. Poor metabolizer status has been identified for multiple clinically important enzymes including CYP2D6, CYP2C19, and CYP2C9.

2. Some patients carry multiple copies of a gene encoding a drug-metabolizing enzyme, producing far more of that enzyme than normal. These patients are called ultrarapid metabolizers. If an ultrarapid metabolizer is given a standard dose of a drug eliminated by that enzyme, which of the following best predicts what will happen?

A) The drug will be metabolized so rapidly that plasma concentrations may never reach or remain at therapeutic levels — the patient may experience treatment failure at a standard dose that works in most patients; ultrarapid metabolizers often require higher than standard doses to achieve therapeutic concentrations
B) The drug will accumulate to toxic levels because the excess enzyme overwhelms the normal elimination pathway and produces toxic metabolites in greater quantity than normal enzyme levels generate
C) The ultrarapid metabolizer will have identical drug concentrations to a normal metabolizer because the body automatically regulates plasma drug concentrations to a fixed set point regardless of enzyme activity
D) Ultrarapid metabolism affects drug elimination but absorption is enhanced proportionally, so plasma concentrations are maintained at normal levels despite faster hepatic clearance
E) Ultrarapid metabolizers are protected from all drug adverse effects because faster elimination prevents any drug from reaching toxic concentrations regardless of dose

ANSWER: A

Rationale:

Ultrarapid metabolizers represent the opposite problem from poor metabolizers — the drug is eliminated so rapidly it cannot build up to therapeutic concentrations. A standard dose producing effective concentrations in a normal metabolizer may produce concentrations too low to be effective in an ultrarapid metabolizer, a clinically important cause of apparent treatment failure that is entirely genetic in origin. CYP2D6 ultrarapid metabolizers may fail to respond to standard doses of antidepressants, antipsychotics, or beta-blockers. However, for prodrugs converted to active metabolites by the same enzyme, ultrarapid metabolism creates the opposite danger — the active metabolite is generated too rapidly, causing toxicity. The codeine-to-morphine conversion via CYP2D6 is the classic dangerous example: ultrarapid metabolizers can develop morphine toxicity from standard codeine doses, serious enough to trigger regulatory warnings. Options B, C, D, and E each contain fundamental pharmacokinetic inaccuracies about the consequences of ultrarapid metabolism.

3. Codeine is a prodrug with little analgesic activity itself — it must be converted to morphine by CYP2D6 in the liver to produce pain relief. A patient prescribed codeine after surgery is a CYP2D6 poor metabolizer. Which of the following best predicts her response?

A) She will develop morphine toxicity because poor metabolizers convert all codeine directly to morphine without intermediate metabolic steps
B) She will respond normally to codeine because the liver automatically activates alternative enzymes to convert codeine to morphine when CYP2D6 is absent
C) She will experience greater pain relief than a normal metabolizer because poor metabolizers absorb more codeine from the gastrointestinal tract, compensating for reduced hepatic conversion
D) She will experience little or no pain relief because she cannot convert codeine to its active form morphine — the prodrug remains largely unactivated in the circulation; poor metabolizers of CYP2D6 receive essentially no analgesic benefit from codeine
E) Poor metabolizer status only slows the rate of codeine conversion — she will eventually achieve the same pain relief as a normal metabolizer but with a delayed onset of analgesia

ANSWER: D

Rationale:

Codeine's analgesic mechanism depends entirely on its conversion to morphine by CYP2D6. A CYP2D6 poor metabolizer cannot perform this conversion effectively — the prodrug remains as codeine in the circulation, providing minimal analgesia. This is a clinically significant cause of analgesic failure that is entirely genetic in origin. Approximately 5-10% of Europeans are CYP2D6 poor metabolizers, meaning a meaningful proportion of patients prescribed codeine receive essentially no pain relief. Codeine is therefore not an appropriate analgesic for known CYP2D6 poor metabolizers.

4. Clopidogrel is a prodrug that must be converted by CYP2C19 in the liver to its active form to prevent blood clots after coronary stent placement. A patient who is a CYP2C19 poor metabolizer receives clopidogrel after stenting. Which of the following best predicts the pharmacogenomic consequence?

A) The patient will develop excessive bleeding because poor metabolizers accumulate the parent drug clopidogrel, which has direct anticoagulant properties independent of its activated metabolite
B) CYP2C19 poor metabolizer status affects clopidogrel's pharmacodynamics but not its pharmacokinetics — the active metabolite is produced normally but platelet receptor sensitivity to it is reduced
C) The consequence is clinically insignificant — alternative platelet inhibition pathways compensate fully for the loss of CYP2C19-dependent clopidogrel activation in poor metabolizers
D) The patient will have excellent antiplatelet protection because poor metabolizers absorb more clopidogrel from the intestine, compensating for reduced hepatic conversion to the active metabolite
E) The patient will be at increased risk of stent thrombosis and heart attack because she cannot adequately convert clopidogrel to its active metabolite — without sufficient active drug, platelets are not adequately inhibited and the stent may clot; CYP2C19 poor metabolizer status carries an FDA boxed warning for clopidogrel

ANSWER: E

Rationale:

The clopidogrel-CYP2C19 interaction is one of the most clinically significant pharmacogenomic associations in cardiovascular medicine. Clopidogrel requires hepatic CYP2C19-mediated activation to generate the active thiol metabolite that irreversibly inhibits the platelet P2Y12 ADP receptor and prevents platelet aggregation. In CYP2C19 poor metabolizers this activation step is substantially impaired — less active metabolite is generated, platelet inhibition is inadequate, and the risk of stent thrombosis and major adverse cardiovascular events is significantly increased. This association is strong enough that the FDA added a boxed warning to clopidogrel's prescribing information. In patients known to be CYP2C19 poor metabolizers, alternative antiplatelet agents not requiring CYP2C19 activation — such as prasugrel or ticagrelor — are generally preferred. Options B and C incorrectly minimize the clinical significance of this well-characterized pharmacogenomic interaction.

5. Warfarin has a very narrow therapeutic index. Two genes — CYP2C9 (encoding the enzyme that metabolizes warfarin) and VKORC1 (encoding warfarin's target enzyme) — strongly influence how much warfarin a patient needs. A patient carries variants that reduce both CYP2C9 activity and VKORC1 expression. Which of the following best predicts her warfarin dose requirement?

A) The two genetic variants cancel each other out — reduced CYP2C9 activity increases warfarin concentration while reduced VKORC1 expression reduces warfarin sensitivity, producing a normal net effect requiring a standard dose
B) Both variants act in the same direction to increase warfarin sensitivity: reduced CYP2C9 activity slows warfarin metabolism causing higher plasma concentrations at any given dose; reduced VKORC1 expression means the target enzyme is more sensitive to inhibition at any given warfarin concentration; together these variants predict a substantially reduced dose requirement — this patient may need only 1-2 mg per day versus the population average of 5 mg per day, and starting at a standard dose would put her at high risk of serious bleeding
C) Reduced CYP2C9 activity has no effect on warfarin because warfarin is primarily eliminated by the kidneys rather than by CYP2C9-mediated hepatic metabolism
D) VKORC1 variants affect warfarin's pharmacokinetics — they alter the rate of warfarin absorption from the gastrointestinal tract rather than its pharmacodynamic sensitivity at the target enzyme
E) Genetic testing for CYP2C9 and VKORC1 is only relevant for patients who have already experienced a bleeding event on warfarin — it has no role in prospective dose prediction before starting therapy

ANSWER: B

Rationale:

The warfarin pharmacogenomics example is particularly instructive because it involves both a pharmacokinetic gene (CYP2C9, affecting warfarin elimination rate) and a pharmacodynamic gene (VKORC1, affecting target sensitivity). These two genes together explain a large fraction of the interindividual variability in warfarin dose requirements. When both unfavorable variants are present, their effects compound: the patient both accumulates more warfarin (pharmacokinetic effect) and is more sensitive to its action at any given concentration (pharmacodynamic effect). A patient carrying both variants may require only a fraction of the standard dose — and starting at a population-average dose may cause life-threatening bleeding within the first days of therapy.

6. Abacavir is an antiretroviral drug used to treat HIV infection. Approximately 5-8% of patients develop a severe hypersensitivity reaction — fever, rash, and multi-organ inflammation — that can be life-threatening on rechallenge. This reaction is almost exclusively seen in carriers of a specific HLA-B gene variant. Which of the following best describes what this pharmacogenomic association means clinically?

A) Carriers of the HLA-B variant should receive a higher abacavir dose — the variant reduces abacavir absorption and dose escalation is needed to achieve therapeutic HIV-suppressing concentrations
B) The HLA-B variant association is too weak to be clinically useful — since only 5-8% of patients react, testing is not cost-effective compared to monitoring all patients clinically for early signs of hypersensitivity
C) Patients who carry the HLA-B*5701 variant should not receive abacavir — genetic screening before prescribing identifies carriers and prevents them from receiving a drug that would cause a potentially fatal hypersensitivity reaction; this pharmacogenomic safety test has been incorporated into prescribing guidelines worldwide and has virtually eliminated abacavir hypersensitivity from clinical practice where implemented
D) HLA-B variant testing is required only in patients with a personal or family history of drug hypersensitivity — patients without such history can receive abacavir without prior genetic testing
E) The HLA-B variant causes abacavir to be metabolized to a reactive toxic metabolite — carriers require dose reduction rather than complete avoidance of the drug

ANSWER: C

Rationale:

The abacavir-HLA-B*5701 association is a landmark achievement of pharmacogenomics and a model for how genetic testing can prevent serious drug-induced harm. Patients who carry the HLA-B*5701 allele have an immune system that recognizes abacavir as a foreign antigen, triggering a severe delayed hypersensitivity reaction that can be fatal upon rechallenge. The test is highly predictive — almost all cases of abacavir hypersensitivity occur in HLA-B*5701 carriers, and non-carriers have very low risk. Prospective genetic screening before prescribing abacavir identifies carriers, excludes them from abacavir therapy, and virtually eliminates the hypersensitivity syndrome.

7. A patient of Han Chinese ancestry is being considered for allopurinol therapy for gout. The physician orders a genetic test before prescribing. Which of the following best explains why the patient's ancestry influenced this prescribing decision?

A) Allopurinol is metabolized differently in Han Chinese patients due to a CYP3A4 variant common in this population — the dose must be halved to avoid drug accumulation and toxicity
B) Han Chinese patients have a pharmacodynamic variant in the xanthine oxidase enzyme that makes allopurinol less effective — an alternative drug class must be used rather than any allopurinol dose adjustment
C) The physician is testing for CYP2D6 ultrarapid metabolizer status, which is more prevalent in Asian populations and requires dose escalation to achieve adequate uric acid lowering
D) A variant of the HLA-B gene — specifically HLA-B*5801 — is far more common in Han Chinese and other Asian populations than in European populations; carriers of this variant are at substantially elevated risk of severe cutaneous adverse reactions to allopurinol including Stevens-Johnson syndrome and toxic epidermal necrolysis; genetic screening before prescribing identifies carriers who should receive an alternative urate-lowering agent
E) The genetic test is an administrative requirement for prescribing any urate-lowering drug to patients of Asian ancestry — it is a documentation requirement unrelated to drug selection or dose adjustment

ANSWER: D

Rationale:

The allopurinol-HLA-B*5801 association illustrates how pharmacogenomics intersects with population genetics. The HLA-B*5801 allele is present in approximately 6-8% of Han Chinese individuals but in less than 1% of European-ancestry populations. Carriers of this allele are at dramatically elevated risk of developing severe cutaneous adverse reactions to allopurinol — including Stevens-Johnson syndrome and toxic epidermal necrolysis, which have mortality rates of 10-30%. Because the allele is so much more common in Han Chinese and other Asian populations, genetic screening before prescribing allopurinol is recommended by prescribing guidelines in multiple countries. Non-carriers can receive allopurinol safely. This example illustrates that pharmacogenomic risk can vary substantially between population groups, and that ancestry can be a clinically relevant trigger for genetic testing. The principle — match the drug to the patient's genetic profile to prevent harm — is identical to the abacavir-HLA-B*5701 example but applies to a different drug and a different at-risk population.

8. A child with leukemia is about to receive a thiopurine chemotherapy drug. Before starting, the physician orders testing for the thiopurine methyltransferase (TPMT) gene. Low TPMT enzyme activity causes thiopurine drugs to accumulate as toxic metabolites in bone marrow cells, causing potentially fatal bone marrow suppression. Which of the following best explains the purpose of testing TPMT before starting therapy?

A) TPMT testing identifies patients with reduced or absent TPMT activity who are at high risk of severe, potentially fatal bone marrow suppression from standard thiopurine doses; patients with low or absent TPMT activity require substantially reduced doses — or in the case of complete TPMT deficiency, an alternative drug — to prevent life-threatening myelosuppression; this is pharmacogenomic testing used prospectively to prevent a predictable, genetically determined adverse drug reaction
B) TPMT testing identifies patients who will not respond to thiopurine drugs at all — TPMT-deficient patients should receive an entirely different class of chemotherapy rather than any adjusted thiopurine dose
C) TPMT testing measures kidney function indirectly — the test estimates glomerular filtration rate to guide dose adjustment of renally eliminated thiopurine metabolites in patients with renal impairment
D) TPMT testing identifies ultrarapid metabolizers who will eliminate thiopurines too quickly — the test guides dose escalation in fast metabolizers to ensure therapeutic drug concentrations are achieved for adequate leukemia treatment
E) TPMT testing is performed after thiopurine therapy begins to monitor for early development of bone marrow toxicity — it is a reactive monitoring tool with no role in prospective dose selection before starting the drug

ANSWER: A

Rationale:

TPMT pharmacogenomics is one of the most established clinical applications of pharmacogenomic testing in oncology. The TPMT enzyme inactivates thiopurine drugs by methylation. In patients with reduced or absent TPMT activity — approximately 10% of the population has intermediate activity and 0.3% has very low or absent activity — thiopurine drugs accumulate as highly toxic 6-thioguanine nucleotides in bone marrow cells, causing severe, prolonged, and potentially fatal bone marrow suppression at doses safe in normal patients. Prospective TPMT testing allows dose individualization: normal activity patients receive standard doses; intermediate activity patients receive reduced doses; very low or absent activity patients receive substantially reduced doses or alternative drugs.

9. A student asks: "If pharmacogenomic testing can predict how a patient will respond to a drug, why don't we test every patient for every relevant gene before prescribing anything?" Which of the following best captures the most accurate and complete answer?

A) Pharmacogenomic testing is currently illegal outside clinical trials in most countries — routine clinical genotyping is prohibited by regulations that have not yet been updated to accommodate genomic medicine
B) Pharmacogenomic testing is only useful for predicting adverse reactions — it cannot predict therapeutic response or efficacy, limiting its clinical utility to a small number of drug-safety screening applications
C) While the principle is sound, practical limitations apply: not all drug-gene interactions have sufficient clinical evidence to change prescribing; testing infrastructure and interpretation expertise are not universally available; cost-effectiveness varies depending on allele frequency, severity of the interaction, and whether test results are actionable; testing is most valuable when a result will genuinely change clinical management; guidelines are evolving to identify which gene-drug pairs have sufficient evidence to justify routine clinical genotyping
D) All clinically significant pharmacogenomic associations have already been identified and incorporated into standard prescribing guidelines — there are no remaining undiscovered gene-drug pairs of clinical importance requiring further research
E) Pharmacogenomic test results are too variable to be clinically useful — the same genetic variant produces unpredictably different clinical outcomes in different patients, making results uninterpretable for individual prescribing decisions in routine practice

ANSWER: C

Rationale:

This question asked you to think critically about the practical implementation of pharmacogenomics rather than just its scientific basis. The principle — match drug to patient genotype — is sound, but rational deployment requires weighing evidence quality, clinical actionability, cost-effectiveness, and infrastructure. Testing is most clearly justified when the gene-drug interaction is well-characterized, the clinical consequence is serious, the test result will change management, and the test is feasible in the clinical setting. Examples meeting these criteria include HLA-B*5701 before abacavir, TPMT before thiopurines, and CYP2C19 before clopidogrel in high-risk cardiovascular patients. For many other drug-gene interactions the evidence is still accumulating or the clinical actionability is less clear.

10. A physician reviews a pharmacogenomic test result showing a patient is a CYP2D6 poor metabolizer. The patient is about to be started on a drug primarily metabolized by CYP2D6. The test report recommends either choosing a different drug or starting at a substantially lower dose with careful monitoring. Which of the following best explains the pharmacological reasoning behind this recommendation?

A) CYP2D6 poor metabolizers absorb drugs more slowly from the gastrointestinal tract — the lower dose compensates for reduced absorption rate rather than altered hepatic elimination
B) Poor metabolizer status reduces the drug's pharmacodynamic effect at its receptor — the dose reduction compensates for decreased receptor sensitivity rather than altered drug concentration
C) The recommendation is precautionary only — CYP2D6 poor metabolizers virtually never experience clinically significant drug accumulation because alternative metabolic pathways fully compensate for absent CYP2D6 activity in all patients
D) The dose reduction applies only if the drug is given intravenously — for oral drugs, gastrointestinal first-pass effects by CYP2D6 are the main elimination pathway and poor metabolizer status does not affect systemic drug concentrations meaningfully
E) As a CYP2D6 poor metabolizer this patient will eliminate the drug more slowly than normal — the drug will accumulate to higher plasma concentrations than intended at a standard dose; if the drug has a narrow therapeutic index, standard dosing may produce toxicity; starting lower or using an alternative drug accounts for the reduced metabolic clearance and aims to achieve the same plasma concentration target that standard dosing achieves in a normal metabolizer

ANSWER: E

Rationale:

This question connects the pharmacogenomic concept of poor metabolizer status directly to the pharmacokinetic consequences covered in Module 2. A CYP2D6 poor metabolizer has reduced hepatic clearance of CYP2D6 substrates — the drug is eliminated more slowly, accumulates to higher concentrations, and has a longer effective half-life. For a drug with a narrow therapeutic index, this accumulation can shift the patient from the therapeutic range into toxicity at a dose perfectly safe in a normal metabolizer. The dose adjustment recommendation is pharmacokinetically rational: by starting lower, the physician aims to achieve plasma concentrations comparable to what standard dosing achieves in a patient with normal CYP2D6 activity. This is individualized pharmacokinetic dosing — using genetic information to predict pharmacokinetic differences and prevent a toxic event before it occurs.

11. A physician reads that a new drug has a pharmacogenomic association involving a hepatic uptake transporter. Patients carrying a variant in this transporter gene have reduced hepatic uptake of the drug, so less drug reaches the liver where it acts. Which pharmacokinetic process is primarily affected, and what is the clinical consequence?

A) The transporter variant affects renal excretion — reduced hepatic uptake means more drug is available for renal elimination, shortening the drug's half-life and requiring more frequent dosing to maintain therapeutic concentrations
B) The transporter variant affects drug distribution — reduced hepatic uptake means the drug distributes less into liver tissue; patients with this variant will have higher plasma drug concentrations but lower drug concentrations at the hepatic site of action, potentially requiring dose adjustment to achieve adequate therapeutic levels at the target organ despite apparently adequate plasma concentrations
C) The transporter variant affects drug absorption from the gastrointestinal tract — hepatic transporters are expressed on intestinal enterocytes and govern oral bioavailability rather than hepatic tissue distribution
D) The transporter variant has no pharmacokinetic consequence — only CYP enzymes, not transporters, are pharmacokinetically relevant to drug disposition in clinical practice
E) The transporter variant affects drug metabolism — hepatic uptake transporters are required for CYP enzymes to access drug substrates, so reduced uptake directly reduces CYP-mediated metabolism and causes systemic drug accumulation

ANSWER: B

Rationale:

Drug transporters represent an important category of pharmacogenomic variation beyond CYP enzymes. Hepatic uptake transporters — particularly the organic anion transporting polypeptide (OATP) family encoded by solute carrier organic anion transporter (SLCO) genes — carry drugs from portal blood into hepatocytes where they undergo metabolism or exert pharmacological effect. The SLCO1B1 (solute carrier organic anion transporter family member 1B1) c.521T>C variant reduces OATP1B1 (organic anion transporting polypeptide 1B1) transporter activity, impairing hepatic uptake of statins such as simvastatin. As a result, statins accumulate in the systemic circulation at higher concentrations than intended while achieving lower hepatic concentrations. The increased systemic statin exposure — particularly in skeletal muscle — increases the risk of statin-induced myopathy and rhabdomyolysis. This illustrates that pharmacogenomics encompasses transporter genes as well as enzyme genes, and that the pharmacokinetic process affected determines the clinical consequence.

12. A medical student asks: "Does pharmacogenomic variation only affect pharmacokinetics — how the body handles the drug — or can it also affect pharmacodynamics — how the drug acts at its target?" Which of the following best answers this question?

A) Pharmacogenomic variation affects only pharmacokinetics — variations in receptor genes do not produce clinically significant effects on drug response because receptor structure is highly conserved across all human populations
B) Pharmacogenomic variation affects only pharmacodynamics — genetic variants in receptors and targets are the primary source of interindividual drug response variability; enzyme variants play no clinically meaningful role in drug outcomes
C) Pharmacogenomic variation is clinically relevant only for psychotropic drugs — the nervous system is uniquely sensitive enough that genetic variants produce measurable differences; other organ systems are not meaningfully affected by pharmacogenomic variation
D) Pharmacogenomic variation can affect both pharmacokinetics and pharmacodynamics: pharmacokinetic pharmacogenomics includes variation in drug-metabolizing enzymes and transporters that alter drug plasma concentrations; pharmacodynamic pharmacogenomics includes variation in drug targets — the VKORC1 gene variant alters warfarin's target enzyme sensitivity, and HLA gene variants alter immune recognition of drug-protein complexes; together these categories explain why the same drug can produce dramatically different clinical outcomes in genetically distinct individuals
E) Pharmacogenomic variation produces statistically detectable differences in research studies but is rarely large enough to be clinically significant for individual patient management decisions in routine clinical practice

ANSWER: D

Rationale:

This question asked you to synthesize the pharmacogenomics module with the earlier modules on pharmacokinetics and pharmacodynamics. Pharmacogenomic variation affects both systems. Pharmacokinetic pharmacogenomics — variation in enzymes and transporters — determines how much drug reaches the target. Pharmacodynamic pharmacogenomics — variation in drug targets, receptors, or immune recognition proteins — determines what happens when the drug arrives. The warfarin example illustrates both dimensions simultaneously: CYP2C9 variation affects warfarin plasma concentration (pharmacokinetic), while VKORC1 variation affects warfarin's inhibitory effect at its target enzyme (pharmacodynamic). The abacavir and allopurinol HLA examples represent pharmacodynamic pharmacogenomics in the immune system. Understanding that pharmacogenomics operates across both domains is essential for interpreting pharmacogenomic test results correctly and for anticipating where genetic variation will be clinically significant.

13. A patient is a CYP2D6 extensive metabolizer with normal enzyme function. Three months later a new drug is added to her regimen — a potent CYP2D6 inhibitor. Which of the following best predicts what will happen to the first drug's plasma concentration, and what concept does this illustrate?

A) The first drug's plasma concentration will increase because the new drug inhibits CYP2D6, reducing metabolism of the first drug — this drug interaction converts the patient's functional pharmacokinetic status from extensive metabolizer to effectively poor metabolizer; a patient who was genetically an extensive metabolizer now behaves pharmacokinetically like a poor metabolizer because the enzyme is pharmacologically suppressed; this illustrates that drug interactions and pharmacogenomics are not separate phenomena but operate on the same biological systems and must be considered together
B) The first drug's plasma concentration will decrease because CYP2D6 inhibition by the new drug activates compensatory upregulation of alternative CYP enzymes that metabolize the first drug more rapidly than before
C) The first drug's plasma concentration will remain unchanged because a patient's genetically determined extensive metabolizer status is fixed and cannot be functionally altered by any drug interaction regardless of the inhibitor's potency
D) The new drug will be metabolized instead of the first drug, protecting it from CYP2D6 inhibition by serving as a competitive decoy substrate that occupies the enzyme completely
E) The interaction is only relevant if the patient is also taking a third drug — CYP2D6 inhibition only produces clinically significant interactions when three or more drugs are simultaneously present

ANSWER: A

Rationale:

This question illustrates one of the most important conceptual links in pharmacology — the interaction between pharmacogenomics and drug-drug interactions. A patient who is genetically a CYP2D6 extensive metabolizer has normal enzyme activity. When a potent CYP2D6 inhibitor is added, that enzyme activity is pharmacologically suppressed — the patient now metabolizes CYP2D6 substrates slowly, just as a genetic poor metabolizer would. This phenomenon is called phenoconversion: a drug interaction converts the patient's functional metabolizer phenotype from extensive to poor. The clinical consequence is drug accumulation identical to that seen in a genetic poor metabolizer. This means understanding a patient's pharmacogenomic profile is insufficient on its own — the clinician must also consider what other drugs might phenoconvert that profile. The two systems — genetic variation and drug interactions — operate on the same enzymes and must be considered together for accurate clinical pharmacokinetic prediction.

14. A physician tells a patient that before starting a new drug, a genetic test will be done to guide the initial dose. The patient asks: "If my genetic test tells you the right dose, do I need to come back for any further monitoring?" Which of the following best captures the physician's most accurate response?

A) Yes — pharmacogenomic test results predict the correct dose with such precision that no subsequent monitoring or dose adjustment is ever needed once the initial dose is established based on genotype alone
B) Yes, but only if additional genetic variants are discovered in future — a single repeat test may then be required for a one-time dose recalculation
C) No — pharmacogenomic testing predicts the starting dose based on genetic factors affecting drug metabolism or response, but other factors change over time and require ongoing monitoring: organ function fluctuates with age, illness, and disease progression; concurrent medications may inhibit or induce the relevant enzyme; clinical response is the ultimate measure of whether the dose is right; genetic information is one valuable input into dose individualization but is not a permanent substitute for clinical monitoring
D) Yes, but only for narrow therapeutic index drugs — for wide therapeutic index drugs ongoing monitoring is always required after any genetic test regardless of the result
E) The answer depends entirely on the patient's age — patients under 50 may rely on pharmacogenomic results permanently while patients over 50 always require repeat monitoring regardless of genotype

ANSWER: C

Rationale:

Pharmacogenomic testing provides valuable but incomplete information about the right drug and dose for an individual patient. Genetic variants in metabolizing enzymes are fixed at birth and do not change — a patient's CYP2D6 genotype today is the same as it will be in 30 years. However, a patient's functional drug metabolism changes continuously with age-related organ function decline, intercurrent illness, and concurrent medications. A genetically extensive metabolizer who develops significant hepatic impairment will have reduced drug metabolism despite a favorable genotype. A patient started on a potent CYP inhibitor after pharmacogenomic testing will be effectively phenoconverted regardless of genotype. Additionally, the patient's clinical response — the ultimate measure of whether the dose is right — requires ongoing assessment. Pharmacogenomic testing improves the starting point for dose individualization; it does not eliminate the need for clinical pharmacological monitoring throughout the course of therapy.

15. A physician is about to prescribe clopidogrel after cardiac stent placement. She knows CYP2C19 poor metabolizer status substantially reduces clopidogrel efficacy and increases stent thrombosis risk. She also notes the patient is taking omeprazole — a proton pump inhibitor that inhibits CYP2C19. Which of the following best synthesizes the pharmacogenomic and drug interaction reasoning informing her prescribing decision?

A) The omeprazole-CYP2C19 inhibition is irrelevant if the patient is a CYP2C19 extensive metabolizer — genetic extensive metabolizer status provides complete protection against the pharmacological effects of CYP2C19 inhibition by any co-administered drug
B) Since both the pharmacogenomic variant and the drug interaction affect the same enzyme their effects cancel each other out — a patient who is a poor metabolizer genetically and also taking a CYP2C19 inhibitor will paradoxically have normal clopidogrel activation through a compensatory feedback mechanism
C) The drug interaction takes complete priority over the genetic consideration — phenotypic drug interactions always override pharmacogenomic predictions, so the physician should focus only on the omeprazole interaction and disregard the patient's CYP2C19 genotype entirely
D) The physician should proceed with clopidogrel and omeprazole at standard doses — the clinical significance of the CYP2C19-clopidogrel interaction has been substantially overstated and does not require prescribing modification in routine practice
E) The physician must consider both the patient's CYP2C19 genotype and the omeprazole interaction together: if the patient is a CYP2C19 poor metabolizer, clopidogrel is likely to be ineffective regardless of omeprazole; if the patient is an extensive metabolizer, omeprazole's CYP2C19 inhibition may phenoconvert him toward poor metabolizer functional status, reducing clopidogrel activation; in either scenario this combination of a CYP2C19-dependent prodrug with a CYP2C19 inhibitor in a high-stakes cardiovascular context warrants either an alternative antiplatelet drug (prasugrel or ticagrelor) or an alternative acid suppression agent that does not inhibit CYP2C19 such as pantoprazole

ANSWER: E

Rationale:

This question asked you to apply pharmacogenomics and drug interaction reasoning simultaneously to a high-stakes clinical scenario — exactly the kind of integrated thinking that Tier 1 will require. Clopidogrel requires CYP2C19 for activation. Two independent factors can reduce CYP2C19 activity in this patient: genetic poor metabolizer status (little CYP2C19 activity to begin with) and omeprazole (pharmacological inhibition of CYP2C19 even in extensive metabolizers, potentially converting their functional status toward poor metabolizer). These two factors compound rather than cancel — together they represent a greater threat to clopidogrel efficacy than either alone. In a patient who has just received a coronary stent, where inadequate antiplatelet therapy can cause stent thrombosis and myocardial infarction, this combined risk is clinically unacceptable. The rational prescribing response addresses both factors simultaneously.

BEFORE YOU MOVE ON

You have worked through 15 questions covering the pharmacogenomic basis of variable drug response — CYP2D6, CYP2C19, and CYP2C9 metabolizer phenotypes, VKORC1 sensitivity variation, HLA-B*5701 and HLA-B*1502 screening, TPMT testing, and the distinction between pharmacokinetic and pharmacodynamic genetic variation. Pharmacogenomics is increasingly integrated into clinical prescribing — clopidogrel after cardiac stenting, abacavir screening in HIV, warfarin initiation, and thiopurine dosing in oncology all involve the principles covered here. Tier 1 applies these concepts to clinical scenarios where a patient's genetic profile changes the prescribing decision.